HC Wainwright & Co. Reiterates Buy on Mirum Pharmaceuticals, Maintains $130 Price Target

HC Wainwright & Co. analyst Swayampakula Ramakanth reiterates Mirum Pharmaceuticals (NASDAQ:MIRM) with a Buy and maintains $130 price target.